Remedy's Resonant quarter shows what a mid-size hit can and cannot fix

Remedy Entertainment’s third-quarter revenue hit €39.6 million, up 226 percent, after Control Resonant launched on September 24.¹² That filing is the news this column reacts to: what a fastest-selling title actually buys a mid-size studio.

The plain answer is a repaired quarter and a wider door, not a finished year. Operating profit was €0.6 million against a €16.4 million loss a year earlier.¹² Game sales and royalties did the heavy lift at €35 million, up from €6 million, on preorders and the first seven days of sales.¹ The physical release fell after the period, on October 15. Unit sales have since passed one million—Remedy’s fastest title to date, quicker than Alan Wake 2’s path to the same mark.¹³

Nearly half of Resonant players were new to Control.¹² The US accounted for nearly half of PC and console sales; outstanding wishlists still total 2.4 million.¹ The 2019 Control game sold better in the quarter as well.¹² CEO Jean-Charles Gaudechon called the launch “a defining milestone for the company” and said the priority is to get Resonant to more players, with sales over the rest of the year set to define financial year 2026.¹²

That is the mid-size case worth stating clearly. A studio that self-publishes a franchise sequel at this scale—and Remedy’s model now puts royalties, platform fees, and an Annapurna share of Resonant on its own books, in line with the self-publish path it has taken on larger Control releases—can flip a brutal comparison quarter without waiting on someone else’s slate.¹⁴ Development fees from the Max Payne 1 & 2 remake and a final Resonant accrual still added €4.3 million.¹ Alan Wake was quieter; Alan Wake 2’s capitalized costs are fully depreciated.¹ Catalog and pipeline both move the needle. The hit is the hinge.

The fair counterpoint is that speed is not consensus. Resonant was critically divisive and the lowest-rated of Remedy’s recent big three, and a three-week million does not prove the creative bet will compound on its own.²³ Royalty costs fall only after initial investments are recouped; depreciation and marketing both peaked around launch.¹ The profit line is thin because the cost line is real. Gaudechon has framed Resonant as a first step into large action role-playing games and as the moment Control stands as a true franchise, with other projects still in the pipeline.¹⁵ Belief is not a substitute for the next print.

I would change this reading if full-year 2026 failed to hold after the launch spike, if the new-player share proved to be a first-week blip, or if that 2.4 million wishlist base did not convert. The outlook is the remainder of the year and the Max Payne work. One filing made the quarter. The next ones decide the model.

Our read: A self-published million-seller can rewrite a mid-size quarter from deep red to thin black. It does not rewrite the cost structure or the year. Wishlist conversion and the rest of 2026 sales are the next stations on the map.

Footnotes

1. GamesIndustry.biz, “Remedy Q3 revenue triples to €39.6m following launch of Control Resonant”. Retrieved November 3, 2026. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

2. Eurogamer, “Remedy revenue soars by 226% following release of Control Resonant, the developer’s fastest-selling game ever”. Retrieved November 3, 2026. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

3. Eurogamer, “Control Resonant becomes the fastest-selling game in Remedy’s history, outpacing Alan Wake 2 and the original Control”. Retrieved November 3, 2026. ↩ ↩²

4. PC Gamer, “Remedy is leaving Epic in the dark place to self-publish Control 2 through a ‘strategic cooperation agreement’ with Annapurna”. Retrieved November 3, 2026. ↩

5. Yle, “Remedyn liikevaihto yli kolminkertaistui Control Resonantin pelimyynnin siivittämänä”. Retrieved November 3, 2026. ↩